<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1584">
  <stage>Registered</stage>
  <submitdate>4/06/2007</submitdate>
  <approvaldate>4/06/2007</approvaldate>
  <nctid>NCT00483171</nctid>
  <trial_identification>
    <studytitle>A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients</studytitle>
    <scientifictitle>A 14-Month, Randomized, Double-Blind,Placebo-Controlled Phase 3 Study To Evaluate The Long-Term Efficacy And Safety of CP-945,598 In Prevention Of Weight Regain In Obese Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>A5351028</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - CP-945,598
Behaviour - Non-pharmacological weight loss program (NPP)
Behaviour - Low Calorie Diet

Placebo Comparator: Placebo - 

Other: Non-pharmacological weight loss program (NPP) - 

Other: Low Calorie Diet - 


Treatment: drugs: CP-945,598
CP-945,598

Behaviour: Non-pharmacological weight loss program (NPP)
Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.

Behaviour: Low Calorie Diet
Low calorie diet

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percent weight regained during the 12 month treatment period after a prior weight loss on the low calorie diet (8 weeks).</outcome>
      <timepoint>14 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To explore the effect of CP 954, 598 on: Waist circumference</outcome>
      <timepoint>14 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To evaluate the safety and tolerability of CP 945,598 urine and blood tests</outcome>
      <timepoint>14 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To explore the effect of CP 954, 598 on: Pharmacodynamic measurements including fasting insulin, fasting plasma glucose, adiponectin</outcome>
      <timepoint>14 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To explore the effect of CP 954, 598 on: Patient reported outcomes: Power of Food Scale and Three factor Eating Scale</outcome>
      <timepoint>14 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>To explore the effect of CP 954, 598 GAD 7 and PHQ 9 self report questionnaires. and C-SSRS semi structured interview</outcome>
      <timepoint>14 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject must be overweight (BMI) &gt;/=30 kg/m2, for subjects without co morbidities;
             &gt;/=27 kg/m2 for subjects with co morbidities

          -  Subjects who are willing and able to comply with 8 week Low Calorie Diet, scheduled
             visits, treatment plan, laboratory tests, and other trial procedures.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participation in a formal weight loss program or significant weight loss (fluctuation
             &gt;5% of total body weight) in the past 3 months.

          -  Subjects with serious medical or psychiatric conditions</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>699</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/01/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Pfizer Investigational Site - Camperdown</hospital>
    <hospital>Pfizer Investigational Site - Kippa Ring</hospital>
    <hospital>Pfizer Investigational Site - Adelaide</hospital>
    <hospital>Pfizer Investigational Site - Bedford Park</hospital>
    <hospital>Pfizer Investigational Site - Heidelberg</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>4021 - Kippa Ring</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>3081 - Heidelberg</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Aarhus</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Frederiksberg C</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Gentofte</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Roskilde</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Almere</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Amsterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Hilversum</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Gauteng</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Pretoria</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine if CP-945,598 is effective in the prevention of
      weight regain in obese subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00483171</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>